

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)ATTY DOCKET NO.  
026083/0119

SERIAL NO.

~~Unassigned~~

09/302,434

APPLICANT  
Klaus Bosslet, et al.FILING DATE  
April 30, 1999

GROUP

Date Submitted to PTO: April 30, 1999

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,873,316	10/1989	MAEDA ET AL.	530	412	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	A2	0 512 905	11/1992	EUROPE				
	A3	0 481 790	04/1992	EUROPE				
	A4	0 511 917	11/1992	EUROPE				
	A5	0 501 215	09/1992	EUROPE				
	A6	0 388 914	09/1992	EUROPE				
	A7	WO 89/10140	11/1989	WIPO				
	A8	WO 90/07861	07/1990	WIPO				

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	A9	MATTES, "BIODISTRIBUTION OF ANTIBODIES AFTER INTRAPERITONEAL OR INTRAVENOUS...", JNCI, 79:4;855-63, Oct. 1987
	A10	KATO ET AL., "ACTIVITY ENHANCEMENT OF A LUNG CANCER-ASSOCIATED HUMAN MONOCLONAL ANTIBODY...", Human Antibodies and Hybridomas, 4:9-14, Jan. 1993
	A11	STAHL, "THE MANNOSE RECEPTOR AND OTHER MACROPHAGE LECTINS", Current Biology Ltd., 4:49-52, 1992.
EXAMINER	DATE CONSIDERED 6/17/02	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: April 30, 1999

ATTY DOCKET NO.  
026083/0119

SERIAL NO.

09/302,434

APPLICANT  
Klaus Bosslet, et al.FILING DATE  
April 30, 1999

GROUP




## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	A12		BAGSHAW ET AL., "ANTIBODY DIRECTED ENZYME PRODRUG THERAPY...", <i>Disease Markers</i> , 9:233-38, 1991.
	A13		MEANS ET AL., "CHEMICAL MODIFICATIONS OF PROTEINS: HISTORY AND APPLNS.", <i>Bioconjugate Chem.</i> , 1:1, 2-12, 1990.
	A14		STEER ET AL., "HEPATIC MEMBRANE RECEPTORS FOR GLYCOPROTEINS", <i>Prog. In Liver Diseases</i> , 8:99 123, 1986

EXAMINER

DATE CONSIDERED

6/17/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

MAY 16 2002

TECH CENTER 1-600-290-1600

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	09/302,434
Filing Date	April 30, 1999
First Named Inventor	Klaus BOSSLET et al.
Group Art Unit	1642
Examiner Name	Jennifer Hunt
Attorney Docket Number	38005-0039

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<del>①</del>	A9	MATTES, "Biodistribution of Antibodies After Intraperitoneal or Intravenous", JNCI, 79:4; 855-63, Oct. 1987	
<del>②</del>	A10	KATO et al., "ACTIVITY ENHANCEMENT OF A LUNG CANCER-ASSOCIATED HUMAN MONOCLONAL ANTIBODY", Human Antibodies and Hybridomas, 4:9-14, Jan. 1993	
<del>③</del>	A11	STAHL, "THE-MANNOSE-RECEPTOR AND OTHER MACROPHAGE LECTINS", Current Biology Ltd., 4:49-52, 1992.	
<del>④</del>	A12	BAGSHAW et al., "ANTIBODY DIRECTED ENZYME PRODRUG THERAPY", Disease Markers, 9:233-38, 1991.	
<del>⑤</del>	A13	MEANS et al., "CHEMICAL MODIFICATIONS OF PROTEINS: HISTORY AND APPLNS.", Bioconjugate Chem., 1:1, 2-12, 1990.	
<del>⑥</del>	A14	STEER et al., "HEPATIC MEMBRANE RECEPTORS FOR GLYCOPROTEINS", Prog. in Liver Diseases, 8:99-123, 1986.	

Examiner  
SignatureDate  
Considered

6/17/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

MAY 16 2002

RECEIVED

#15  
FD  
5-21-02